Newly discovered knowledge pertaining to glucagon and its clinical applications.

Dan Kawamori, Shugo Sasaki

Journal: Journal of diabetes investigation 2023;14(7):829-837

PMID: 37052948

Abstract

Glucagon has been defined as an 'insulin counteracting hormone', which raises blood glucose levels. Recent progress in basic research has shown that glucagon is closely involved in glucose and amino acid metabolism. Additionally, its secretion is intricately, but precisely, regulated by various mechanisms involving molecules in addition to glucose, thus showing its critical role in systemic nutrient metabolism. An innovative dual-antibody-linked immunosorbent assay for glucagon that improves measurement accuracy has been developed, and substantial clinical findings have been obtained using this new system. This discovery expanded the pathophysiological significance of glucagon and accelerated the development of its clinical applications in diabetes.

© 2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

Address: Medical Education Center, Faculty of Medicine, Osaka University, Osaka, Japan.; Postgraduate Medical Training Center, Osaka University Hospital, Osaka University, Osaka, Japan.; Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.